Anserine/carnosine supplementation suppresses the expression of the inflammatory chemokine CCL24 in peripheral blood mononuclear cells from elderly people

Nutrients

Volumn 9, Issue 11, 2017, Pages

  Katakura, Yoshinori ^a   Totsuka, Mamoru ^b   Imabayashi, Etsuko ^c   Matsuda, Hiroshi ^c   Hisatsune, Tatsuhiro ^d  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

Alzheimer s disease; Anserine and carnosine; CCL24; Cognitive function; Elderly people; Inflammatory chemokine; RCT; Verbal memory

Indexed keywords

ANSERINE; BETA ALANINE; CARNOSINE; EOTAXIN 2; HISTIDINE; IMIDAZOLE; LYSINE; AUTACOID; BIOLOGICAL MARKER; CCL24 PROTEIN, HUMAN;

ADULT; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; COGNITIVE FUNCTION TEST; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; FISH MEAT; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PSYCHOLOGIC TEST; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; SHORT FORM 36; VERBAL MEMORY; WECHSLER MEMORY SCALE; AGE; AGED; AGING; BLOOD; COGNITION; DIETARY SUPPLEMENT; DOWN REGULATION; DRUG COMBINATION; DRUG EFFECT; EPISODIC MEMORY; GENETICS; IMMUNOLOGY; JAPAN; MEMORY DISORDER; METABOLISM; MONONUCLEAR CELL; PSYCHOLOGY; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; AGING; ANSERINE; BIOMARKERS; CARNOSINE; CHEMOKINE CCL24; COGNITION; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DOWN-REGULATION; DRUG COMBINATIONS; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; MALE; MEMORY DISORDERS; MEMORY, EPISODIC; MIDDLE AGED; TIME FACTORS; TOKYO; TREATMENT OUTCOME;

EID: 85033447558     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu9111199     Document Type: Article

References (37)

1. Baumgart, M.; Snyder, H.M.; Carrillo, M.C.; Fazio, S.; Kim, H.; Johns, H. Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A population-based perspective. Alzheimer’s Dement. 2015, 11, 718–726. [CrossRef] [PubMed]
2. Lindenberger, U. Human cognitive aging: corriger la fortune? Science 2014, 346, 572–578. [CrossRef] [PubMed]
3. Gutchess, A. Plasticity of the aging brain: new directions in cognitive neuroscience. Science 2014, 346, 579–582. [CrossRef] [PubMed]
4. Farías, G.A.; Guzmán-Martínez, L.; Delgado, C.; Maccioni, R.B. Nutraceuticals: A novel concept in prevention and treatment of Alzheimer’s disease and related disorders. J. Alzheimer’s Dis. 2014, 42, 357–367.
5. Scheltens, P.; Kamphuis, P.J.; Verhey, F.R.; Rikkert, M.G.O.; Wurtman, R.J.; Wilkinson, D.; Twisk, J.W.; Kurz, A. Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial. Alzheimer’s Dement. 2010, 6, 1–10. [CrossRef] [PubMed]
6. Boldyrev, A.A.; Aldini, G.; Derave, W. Physiology and pathophysiology of carnosine. Physiol. Rev. 2013, 93, 1803–1845. [CrossRef] [PubMed]
7. Szczésniak, D.; Budzé n, S.; Kopéc, W.; Rymaszewska, J. Anserine and carnosine supplementation in the elderly: Effects on cognitive functioning and physical capacity. Arch. Gerontol. Geriatr. 2014, 59, 485–490. [CrossRef] [PubMed]
8. Rokicki, J.; Li, L.; Imabayashi, E.; Kaneko, J.; Hisatsune, T.; Matsuda, H. Daily carnosine and anserine supplementation alters verbal episodic memory and resting state network connectivity in healthy elderly adults. Front. Aging Neurosci. 2015, 7, 219. [CrossRef] [PubMed]
9. Hisatsune, T.; Kaneko, J.; Kurashige, H.; Cao, Y.; Satsu, H.; Totsuka, M.; Katakura, Y.; Imabayashi, E.; Matsuda, H. Effect of anserine/carnosine supplementation on verbal episodic memory in elderly people. J. Alzheimer’s Dis. 2016, 50, 149–159. [CrossRef] [PubMed]
10. Kawano, N.; Awata, S.; Ijuin, M.; Iwamoto, K.; Ozaki, N. Necessity of normative data on the Japanese version of the Wechsler Memory Scale-Revised Logical Memory subtest for old-old people. Geriatr. Gerontol. Int. 2013, 13, 726–730. [CrossRef] [PubMed]
11. Villeda, S.A.; Luo, J.; Mosher, K.I.; Zou, B.; Britschgi, M.; Bieri, G.; Stan, T.M.; Fainberg, N.; Ding, Z.; Eggel, A., et al. The ageing systemic milieu negatively regulates neurogenesis and cognitive function. Nature 2011, 477, 90–94. [CrossRef] [PubMed]
12. Huber, A.K.; Giles, D.A.; Segal, B.M.; Irani, D.N. An emerging role for eotaxins in neurodegenerative disease. Clin. Immunol. 2016. [CrossRef] [PubMed]
13. Aoyagi, S.; Sugino, T.; Kajimoto, Y.; Nishitani, M. Safety of long-term administration of CBEX-Dr-containing drink of healthy people. Jpn. Pharmacol. Ther. 2008, 36, 213–224.
14. Aoyagi, S.; Sugino, T.; Kajimoto, Y.; Nishitani, M. Safety of excess administration of CBEX-Dr-containing drink of healthy people. Jpn. Pharmacol. Ther. 2008, 36, 225–235.
15. Kiyohara, Y.; Shinohara, A.; Kato, I.; Shirota, T.; Kubo, M.; Tanizaki, Y.; Fujishima, M.; Iida, M. Dietary factors and development of impaired glucose tolerance and diabetes in a general Japanese population: The Hisayama Study. J. Epidemiol. 2003, 13, 251–258. [CrossRef] [PubMed]
16. Homma, A.; Fukuzawa, K.; Tsukada, Y.; Ishii, T.; Hasegawa, K.; Mohs, R.C. Development of a Japanese version of Alzheimer’s disease Assessment Scale (ADAS). Jpn. J. Geriatr. Psychiatry 1992, 3, 647–655.
17. Mohs, R.C.; Rosen, W.G.; Davis, K.L. The Alzheimer’s disease assessment scale: An instrument for assessing treatment efficacy. Psychopharmacol. Bull. 1983, 19, 448–450. [PubMed]
18. Beck, A.T.; Steer, R.A.; Brown, G.K. Manual for the Beck Depression Inventory, 2nd ed.; Pearson: San Antonio, TX, USA, 1996.
19. Kojima, M.; Furukawa, T.A. Japanese Manual of the Beck Depression Inventory, 2nd ed.; Nihon Bunka Kagakusha: Tokyo, Japan, 2003.
20. Ware, J.E.; Sherbourne, C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care 1992, 30, 474–483. [CrossRef]
21. Lu, Y.; Nyunt, M.S.; Gwee, X.; Feng, L.; Feng, L.; Kua, E.H.; Kumar, R.; Ng, T.P. Life event stress and chronic obstructive pulmonary disease (COPD): Associations with mental well-being and quality of life in a population-based study. BMJ Open 2012, 2, e001674. [CrossRef] [PubMed]
22. Uchida, K.; Shan, L.; Suzuki, H.; Tabuse, Y.; Nishimura, Y.; Hirokawa, Y.; Mizukami, K.; Akatsu, H.; Meno, K.; Asada, T. Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline. Alzheimer’s Dement. 2015, 1, 270–280. [CrossRef] [PubMed]
23. Da Conceicao, V.N.; Dyer, W.B.; Gandhi, K.; Gupta, P.; Saksena, N.K. Genome-wide analysis of primary peripheral blood mononuclear cells from HIV+ patients-pre-and post–HAART show immune activation and inflammation the main drivers of host gene expression. Mol. Cell. Ther. 2014, 2, 11. [CrossRef] [PubMed]
24. Bolstad, B.M.; Irizarry, R.A.; Astrand, M.; Speed, T.P. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19, 185–193. [CrossRef] [PubMed]
25. Gentleman, R.C.; Carey, V.J.; Bates, D.M.; Bolstad, B.; Dettling, M.; Dudoit, S.; Ellis, B.; Gautier, L.; Ge, Y.; Gentry, J., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5, R80. [CrossRef] [PubMed]
26. Saeed, A.I.; Sharov, V.; White, J.; Li, J.; Liang, W.; Bhagabati, N.; Braisted, J.; Klapa, M.; Currier, T.; Thiagarajan, M., et al. TM4: A free, open-source system for microarray data management and analysis. Biotechniques 2003, 34, 374–378. [PubMed]
27. Goto, M.; Abe, O.; Miyati, T.; Yoshikawa, T.; Hayashi, N.; Takao, H.; Inano, S.; Kabasawa, H.; Mori, H.; Kunimatsu, A., et al. Entorhinal cortex volume measured with 3T MRI is positively correlated with the Wechsler Memory Scale-Revised logical/verbal memory score for healthy subjects. Neuroradiology 2011, 53, 617–622. [CrossRef] [PubMed]
28. Lonie, J.A.; Tierney, K.M.; Ebmeier, K.P. Screening for mild cognitive impairment: A systematic review. Int. J. Geriatr. Psychiatry 2009, 24, 902–915. [CrossRef] [PubMed]
29. Grober, E.; Sanders, A.E.; Hall, C.; Lipton, R.B. Free and cued selective reminding identifies very mild dementia in primary care. Alzheimer Dis. Assoc. Disord. 2010, 24, 284–290. [CrossRef] [PubMed]
30. Derby, C.A.; Burns, L.C.; Wang, C.; Katz, M.J.; Zimmerman, M.E.; L’italien, G.; Guo, Z.; Berman, R.M.; Lipton, R.B. Screening for predementia AD: Time-dependent operating characteristics of episodic memory tests. Neurology 2013, 80, 1307–1314. [CrossRef] [PubMed]
31. Son, D.O.; Satsu, H.; Kiso, Y.; Totsuka, M.; Shimizu, M. Inhibitory effect of carnosine on interleukin-8 production in intestinal epithelial cells through translational regulation. Cytokine 2008, 42, 265–276. [CrossRef] [PubMed]
32. Crush, K.G. Carnosine and related substances in animal tissues. Comp. Biochem. Physiol. 1970, 34, 3–30. [CrossRef]
33. Suzuki, T.; Hirano, T.; Suyama, M. Free imidazole compounds in white and dark muscles of migratory marine fish. Comp. Biochem. Physiol. B 1987, 87, 615–619. [CrossRef]
34. Herculano, B.; Tamura, M.; Ohba, A.; Shimatani, M.; Kutsuna, N.; Hisatsune, T. β-alanyl-L-histidine rescues cognitive deficits caused by feeding a high fat diet in a transgenic mouse model of Alzheimer’s disease. J. Alzheimer’s Dis. 2013, 33, 983–997.
35. Kaneko, J.; Enya, A.; Enomoto, K.; Ding, Q.; Hisatsune, T. Anserine (beta-alanyl-3-methyl-L-histidine) improves neurovascular-unit dysfunction and spatial memory in aged AβPPswe/PSEN1dE9 Alzheimer’s-model mice. Sci. Rep. 2017. [CrossRef] [PubMed]
36. Bell, R.D.; Winkler, E.A.; Singh, I.; Sagare, A.P.; Deane, R.; Wu, Z.; Holtzman, D.M.; Betsholtz, C.; Armulik, A.; Sallstrom, J., et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012, 485, 512–516. [CrossRef] [PubMed]
37. Montagne, A.; Barnes, S.R.; Sweeney, M.D.; Halliday, M.R.; Sagare, A.P.; Zhao, Z.; Toga, A.W.; Jacobs, R.E.; Liu, C.Y.; Amezcua, L., et al. Blood-brain barrier breakdown in the aging human hippocampus. Neuron 2015, 85, 296–302. [CrossRef] [PubMed]